Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Y-mAbs Therapeutics

Biotech & Life Sciences · New York City, United States · Founded 2014 · IPO 2018 Unicorn

Clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients

Valuation
$100–500M
Latest valuation · 2026
Unlock exact value
Revenue
$50–100M
Latest reported FY
Unlock exact value
Headcount
<100
Current team size
Unlock exact value

Investors

2 investors on Y-mAbs Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 2 investors entered at this stage
Sofinnova Investments
Scopia Capital

Global footprint

Where Y-mAbs Therapeutics has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States66%
🇩🇰 Denmark33.6%
🇬🇧 United Kingdom1.2%
3 countries shown
Web traffic by country
4.3K monthly visits
across markets
🇺🇸 United States69.8%
🇮🇳 India30.2%
Top 2 markets shown

Patent intelligence

$435k patent portfolio · 8 active families

Estimated portfolio value
$435k
0.13% of valuation · 1792.1× smaller than top peer BioNTech ($780M)
8 active patent families
Where Y-mAbs Therapeutics innovates Molecular biologyAntigenAntigen Binding FragmentCarcinosisCD33

Where Y-mAbs Therapeutics concentrates vs peers

Each axis is a top-10 topic across Y-mAbs Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Y-mAbs Therapeutics

An AI-synthesized read of the highest-engagement posts about Y-mAbs Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Y-mAbs Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.